Lotus is now a fast growing specialty generic company in Asia. Our business model ensures competitive advantage through focused in-house capabilities and a network of partners for enhanced speed and flexibility.
Lotus produces and promotes a unique portfolio of high quality and difficult-to-make pharmaceutical products fueling our growth. Lotus has more than 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US and has more than 250 products in the market.
Lotus started a new phase of growth in 2014 when Alvogen became the majority shareholder and chose Taiwan as its Regional Asian Headquarters. Through Alvogen, Lotus will gain a sales and marketing network in more than 30 countries for boundless opportunities.